Ideas For Now-

stonedinvestor said:
Van can you make head or tails of this:

Ratio call spread in Amarin adjusts bullish view 15:20 AMRN Ratio call spread in Amarin adjusts bullish view. Shares up 34c, or 4.7%, this afternoon at $7.70 with calls leading puts 8:1 and flow concentrated in the September term where a trader sold 10K Sep 7 calls for 1.15 to buy 15k Sep 8 calls for 79c. Net premium on the package is near zero, with trade history suggesting the Sep 7 call sale exits a poition bought Aug 13th near 86c when shares were $1 lower, while the larger Sep 8 call block opens a new position struck 3.7% above spot, expiring in 18 days.
More...
Looks like its a bear call spread, but he has 5K additional calls that'll pay off if it runs north of $8.
If it drops under $7 and stays there by expiration, he pockets $0.36 X 10K X 100.

They must have some kind of FDA approval type thing in the works between now and Sept 18th.
If that's the case, its certainly an interesting trade. If the stock takes off, it'll have to break $10.30 before this guy makes money. If it flops he pockets $360,000.
The worst thing that can happen to the guy is it closes right at $8, in which case he loses $1.15M. Had he not bought the additional 5K contracts, that would be offset by $360K so he would only lose $790,000.
Its a bearish bet really, but with the caveat that the stock really flies if they do get approval. (The extra 5K contracts @ $8)

Thing is, depending on what the drug is I guess, the $10.30 might not be a reach if they get approval. I mean you know how these biotechs move on news like that.
 
Last edited:
100k millenials all got stopped out this morning and now TSLA is probably going to retrace to the overnight high, around $538. So around $60/share if you buy now!!!!! I'm in for 40 shares!
 
Wow get ready to have your mind blown! This HGEN used to be.....

KaloBios Pharmaceuticals files for bankruptcy in wake of Shkreli arrest

(Reuters) - KaloBios Pharmaceuticals Inc, a biotechnology company that fired Chief Executive Martin Shkreli earlier this month after his arrest on charges of securities fraud, filed for Chapter 11 bankruptcy on Tuesday.

Martin Shkreli (C), chief executive officer of Turing Pharmaceuticals and KaloBios Pharmaceuticals Inc, departs U.S. Federal Court after an arraignment following his being charged in a federal indictment filed in Brooklyn relating to his management of hedge fund MSMB Capital Management and biopharmaceutical company Retrophin Inc. in New York

December 17, 2015. REUTERS/Lucas Jackson
The filing comes weeks after KaloBios received financing from Shkreli to avert closing down, only to have those plans upended by his arrest.

Shkreli was arrested on Dec 17 for engaging in what U.S. prosecutors said was a Ponzi-like scheme at his former hedge fund and a pharmaceutical company he previously headed.

Shkreli gained notoriety when, as the chief executive of Turing Pharmaceuticals, he raised the price of a drug used to treat a dangerous parasitic infection to $750 a tablet from $13.50. He resigned as Turing CEO on Dec 18.

KaloBios plans to use bankruptcy to “evaluate its strategic alternatives” and to develop a restructuring plan, according to documents filed with the U.S. bankruptcy court in Wilmington, Delaware.

A chief restructuring officer, Eugene Davis, was appointed on Dec. 23, according to court documents.

KaloBios named Shkreli as its CEO on Nov. 20, after Shkreli and a consortium of investors bought about 70 percent of its shares for an average price of $1.51, and agreed to provide additional financing.

The stock rocketed as high as $45.82 per share after Shkreli’s investment was disclosed.

Shkreli had said that KaloBios’ lenzilumab was a promising candidate for treating rare diseases.


OMG-- was the guy right after all this is the same drug.... They reorganized into HGEN...
 

Humanigen's lenzilumab shows positive effect in COVID-19 in case-control study
Sep. 1, 2020 7:59 AM ET|About:Humanigen, Inc. (HGEN)|
Resultsfrom a 39-patient case-control study in hospitalized COVID-19 patients showed a significant treatment benefit from Humanigen's(OTCQB:HGEN)lenzilumab, its Humaneered anti-human granulocyte macrophage-colony stimulating factor (GM-CSF) monoclonal antibody. The data were just published inMayo Clinic Proceedings.

12 severely ill patients received lenzilumab and 27 contemporaneous matched control patients, identified from an electronic registry of COVID-19 patients matched for age, sex, disease severity and baseline oxygen requirements, received standard-of-care (SOC) treatment.

The relative risk of invasive mechanical ventilation (IMV) and/or death was reduced 80% in the lenzilumab group. Specifically, the risk of IMV and/or death was 8% in lenzilumab-treated patients compared to 41% in the control group (p=0.07).

Median time to resolution of acute respiratory distress syndrome (ARDS) was one day in lenzilumab patients versus eight days in the control group (p<0.01). Median time to discharge was shorter in the lenzilumab group, five days versus 11 days (p=0.008).

Lenzilumab was also associated with a significant reduction in an inflammatory marker called c-reactive protein and improved lymphocyte counts.

The antibody is currently being evaluated in a Phase 3 NIH study called COVID-19 Big Effect.
 
stonedinvestor said:
https://www.sec.gov/Archives/edgar/data/1688786/000168878617000001/jetpackannualreport2017.pdf

I can't find the co though... I think they are private--
Competition

While we currently are leading our field, and believe we have no direct competition, other recreational vehicle or aviation companies such as the manufacturer of light general aviation aircraft and kit aircraft, could copy the JB10 design, or reverse engineer it to create a competing jetpack. Also, a competing company may develop an aviation device similar to the JB10 in terms of size and capabilities, but which does not infringe on any of our intellectual property rights. Examples of potential competitors include: the Martin Aircraft Company, Ehang company (personal commuter drone), the DJI drone company, Kitfox Aircraft, Acro Sport, Inc, Glasair Aviation, Lancair International Inc, AeroMobil and AVIC China,

EHang is a company based in Guangzhou, China that develops and manufactures autonomous aerial vehicles and passenger AAVs which have entered service in China for aerial cinematography, photography, emergency response, and survey missions.Wikipedia

Traded as:NASDAQ:EH-$9.31
More...

Hey Stoney... AMTX is up 33% :D
 
Not Enough Vol 158K.. Need 750K on day....I know it's crazy but think of all the news outlets that will run with this story when they figure out the connection to Shkreli-

Oh it's moving oh no $2.97 van
 
stonedinvestor said:
The whole story here is a long and confusing. Years ago these guys AMRN developed a fish oil pill that's what i remember it helped people remember stuff... I think they waited too long to develop either that or the drug was ok's late for another indication... maybe plaque in the heart... you can see I need one of these pills!!!

So the Co lost their baby to generics or so it looked they are now in Court appealing and it's all going down this week.

Van... This is not for the feint of heart.

IP specialists see panel selection as key to Amarin appeal, says Stifel 07:05
AMRN
Stifel analyst Derek Archila hosted a webcast with two Intellectual Property, or IP, attorneys to get their thoughts on the Vascepa appeal ahead of the oral hearing on September 2, after which he noted to investors that both stressed the importance of the panel selection and its impact on the outcome of the appeal. Both IP specialists see a roughly 55% chance Amarin can win its appeal, but both also highlighted the low odds of reversals in these type of cases, according to Archila, who added that the attorneys think the odds of winning the appeal can swing from 0% to 70% depending on the panel make-up. With the stock trading at roughly $8, which is his current price target, he sees the market factoring in about a 25% chance of Amarin winning the case, said Archila, who assumes shares go to $4 if the decision is affirmed and $20 upon a reversal. He keeps a Hold rating on Amarin shares.

Sumery 55% chance of wining.

If they lose - $8 becomes $4!

If they win- $8 becomes $20!

Now mark Wed Down. On Wed we should know the three panel of judges and if one or two of them are known to be pro big pharma. We Might Place A Bet here. with AMRN....
More...

AHHHHH!
Ok, so my supposition that something big was in the works was correct. I knew it wasn't earnings because they are due in Oct.

Well there ya go.
That option play is pretty damn smart, if the $4/$20 thing is in fact what will happen.
If it goes to $20, this cat makes like $4.85MM, if it goes anywhere below $7, he still makes $360K.
 
You must log in or register to reply here.
Back
Top